News
PFE
30.77
+3.39%
1.01
Catalyst Watch: Tech blitz with Apple, Amazon, Microsoft, and Meta on tap for earnings
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Container Store and Allbirds ahead of their earnings reports. McDonald's, Microsoft, and Boeing among companies due to report on July 29 and 30. Mark Zuckerberg will speak at the SIGGRAPH Conference in Denver.
Seeking Alpha · 6h ago
Noteworthy Friday Option Activity: PFE, FDX, JBHT
NASDAQ · 8h ago
Sangamo rallies for third day in wake of positive gene therapy results
Shares of Sangamo rallies for third day in wake of positive gene therapy results. Sangamo (SGMO) shares gained 40% on Wednesday and 20% on Thursday. Pfizer reported positive results for their gene therapy candidate giroctocogene fitelparvovec in the treatment of hemophilia A.
Seeking Alpha · 9h ago
3 Surprisingly Underrated Stocks to Buy Right Now
Three Motley Fool contributors think AstraZeneca, Pfizer and Viatris are underrated pharmaceutical stocks to buy. Astra Zeneca is a growth machine with impressive prospects. The company expects to generate as much as $80 billion in annual revenue by the end of the decade. These companies are undervalued and deserve more respect.
The Motley Fool · 9h ago
Pfizer Revises Incentive Plans for Employee and Shareholder Alignment
TipRanks · 10h ago
Pharma Stock Roundup: AZN, SNY, ABBV Q2 Earnings, PFE & MRK's Positive Pipeline News
NASDAQ · 11h ago
Bristol-Myers (BMY) Tops on Q2 Earnings, Ups '24 EPS View
NASDAQ · 11h ago
Benjamin Graham Detailed Fundamental Analysis - PFE
NASDAQ · 12h ago
Freeport-McMoRan, Pfizer, Danaher And An Industrial Stock: CNBC's 'Final Trades'
Final Trades: Freeport-McMoRan Inc. And Danaher Corporation. United Rentals posted better-than-expected earnings for its second quarter. Pfizer announced approval of a gene therapy for hemophilia B on July 23. The company also announced a $7.5 billion expansion of its copper mine in Chile.
Benzinga · 12h ago
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know
NASDAQ · 12h ago
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
NASDAQ · 13h ago
Pfizer, Merck bladder cancer therapy endorsed for approval in EU
Merck's Keytruda in combination with Pfizer's Padcev for bladder cancer therapy endorsed for approval in EU. The European Medicines Agency has endorsed the therapy for a type of bladder cancer. The decision was based on interim data from a Phase 3 trial.
Seeking Alpha · 13h ago
Bristol-Myers gains after Q2 beat and late-stage trial win
Bristol-Myers Squibb reports $12.2B in revenue with 9% YoY growth in Q2 2024. The pharma giant also announced a Phase 3 trial win for its experimental antibody therapy, cendakimab. The company exceeded Street forecasts with its Q2 financials.
Seeking Alpha · 13h ago
Pfizer's Q2 Focus: Core Products And New Ventures
Seeking Alpha · 1d ago
What's Going On With Pfizer Stock Thursday?
The European Commission approved Pfizer's DURVEQTIX, a gene therapy for severe and moderately severe hemophilia B. Pfizer shares are slightly higher on the news. The European Commission has already approved the gene therapy in the U.S. And Canada.
Benzinga · 1d ago
Pfizer hemophilia B gene therapy Durveqtix wins EC authorization
Pfizer's hemophilia B gene therapy Durveqtix wins EC authorization. The drug is already approved in the U.S. And Canada under the name Beqvez. The European Commission has granted conditional marketing authorization to Pfizer's gene therapy for hemophili B.
Seeking Alpha · 1d ago
Pfizer Gets EC's Conditional Authorization For Durveqtix Genetherapy In Hemophilia B
NASDAQ · 1d ago
Pfizer Gets European Commission Marketing Approval for Durveqtix
Dow Jones · 1d ago
Seeking Clues to Pfizer (PFE) Q2 Earnings? A Peek Into Wall Street Projections for Key Metrics
NASDAQ · 1d ago
Guru Fundamental Report for PFE - Benjamin Graham
NASDAQ · 1d ago
More
Webull provides a variety of real-time PFE stock news. You can receive the latest news about Pfizer through multiple platforms. This information may help you make smarter investment decisions.
About PFE
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga.